 "Shasun Pharmaceuticals gains on USFDA nod for Carisoprodol tablets")
Carisoprodol tablets in the aforesaid dosages has sales of approximately $38 million. While the dosage of 350mg has few generic players, Shasun expects to be the first marketed generic player in the $16 million Carisoprodol tablets 250mg opportunity, the company said in a release.
The product will be manufactured at the Pondicherry facility of the company and distributed in US through a partner. The product is expected to be launched shortly, the release added.
The stock opened at Rs 398 and touched a high of Rs 408. At 12:30pm, over 176,000 shares were traded on both the stock exchanges.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%